Clinical trial of carbazepine (Tegretol) in trigeminal neuralgia

F. G. CAMPBELL, J. G. GRAHAM, AND K. J. ZILKHA

From The National Hospital, Queen Square, and the Neurological Departments Guy's Hospital, London, and Cardiff Royal Infirmary

Carbazepine, Tegretol (5-carbamyl-dibenz (b,f)-azepin), originally known as G.32883 and introduced in 1959 as an anticonvulsant, was first shown to have some effect in relieving the pain of trigeminal neuralgia by Blom (1962, 1963).

Since then Spillane (1963, 1964), McArdle (1963), and Taylor (1963) have confirmed that this drug has a specific effect in relieving the pain of trigeminal neuralgia in some 60 to 80% of patients.

This paper describes a controlled trial of carbazepine carried out simultaneously at The National Hospital, Queen Square, London, Cardiff Royal Infirmary, and Guy's Hospital, London.

DESIGN OF TRIAL

Patients were admitted to the trial without selection, except for a few who were rejected because of difficulty in attending regularly due to age, infirmity, or geography. Those whose pain was symptomatic of disseminated sclerosis were also excluded.

All patients included in the trial were in pain at the time of entry. Most had not previously received treatment with carbazepine, but the four who had had carbazepine before had been off the drug for at least two months before commencing the trial and were allocated, by chance, equally to the two treatment groups.

Patients were told that two drugs were to be compared for efficacy in relief of pain. The drugs were to be tried alternately for periods of two weeks at a time, and at the end of each fortnight the patient would be seen and questioned about his condition, any unused tablets would be returned, and the next fortnight's tablets issued.

The trial lasted eight weeks, i.e., the subjects passed two periods of alternate fortnights on each drug.

Carbazepine (C) and placebo (P) were issued by the pharmacists according to random number lists in the order C, P, C, P or P, C, P, C, neither patient nor doctor knowing the order of therapy given.

The placebo tablets were made principally of lactose and were indistinguishable in appearance from the active drug. If a patient did not respond to treatment in one week and was in severe pain, he could return early and be changed over to the other treatment. There were four such patients; again two patients were in group C, P, C, P and two in P, C, P, C.

Dosage at each visit began with half a tablet four times daily and if relief was inadequate after 48 hours, it could be increased to 1 tablet four times daily. This schedule was carried out at Guy's Hospital and the National Hospital, but at Cardiff, where a fatality associated with carbazepine had occurred, a maximum dosage of 3 tablets daily was observed, without apparent difference in the results.

At the initial visit information was recorded about age, sex, duration of the illness and number of previous bouts, previous treatment, the division of the trigeminal nerve involved, and the duration and severity of the current bout of pain.

At each subsequent visit enquiries were made about the severity of the pain (severe, moderate, mild), number of paroxysms daily and their duration, and the presence or absence of triggering of the pain by eating, talking, contact, draughts, and other factors. Finally enquiries were made for the known side effects of carbazepine and any others.

NUMBERS IN THE TRIAL AND COMPARISON OF THE TWO TREATMENT GROUPS

Seventy-seven patients were included in the trial at the outset. Of these seven were excluded subsequently for the following reasons: three failed to re-attend after the initial visit, the records of one were lost, one was an unreliable witness, one received the drugs in the wrong order, and one was withdrawn because of a rash after the first period.

Of the remaining 70 patients, 36 began on carbazepine and received their drugs in the order C, P, C, P, and 35 began on placebo and took the drugs in the order P, C, P, C.

The 70 patients ranged in age from 20 to 84, the mean being 59 years, and 34% were males.

The two orders of treatment groups (C, P, C, P and P, C, P, C) were subsequently compared to ascertain whether or not they were similar in all important respects.

The groups were therefore compared for sex, age, number of previous bouts, duration of present bout, and division of nerve affected, and no striking difference was noted. As regards previous treatment, however, only 6% of the C, P, C, P group had been injected for pain as against 29% of the P, C, P, C group. This obviously arose by chance and was not related to the initial distribution by categories of pain in the two groups (Table I).
The results were assessed as regards severity of the pain, the number of paroxysms daily, and the effect of the drug on triggering mechanisms.

SEVERITY OF PAIN A system of scoring was devised for this purpose. Four categories of pain were recorded at each interview as follows: nil = 0, mild = 1, moderate = 2, and severe = 3.

If a patient began at 3 and moved at his next visit to 0, he had scored +3 of a possible +3, and his actual improvement expressed as a percentage of his possible improvement (or upgrading) was called 100%. If, however, he moved from 2 to 1, his score was +1 of a possible +2, i.e., percentage upgrading = 50%.

Similarly, if he deteriorated from 0 to 2 his score was −2 out of a possible −3, and the actual downgrading expressed as a percentage of the possible downgrading = 66%.

Thus, in each group the sum of the actual upgradings or downgradings was expressed as a percentage of the sum of the possible upgradings or downgradings.

These calculations showed that the group which began on carbazepine achieved 58% (51/89) upgrading in the first period, 5% (2/37) in the second period on placebo, 64% (38/59) in the third period on carbazepine, and 15% (4/26) in the last period on placebo. (The figures in brackets are the actual and possible total number of grades.)

The P,C,P,C group, however, was upgraded only 26% (22/86) in the first period on placebo, 41% (27/66) in the second period on carbazepine, 17% (7/41) in the third period on placebo, and 52% (28/54) in the last period on carbazepine. Calculations for downgrading were made and showed a similar trend.

The figures were very greatly in favour of carbazepine. Both groups were upgraded more when on the drug than when on placebo, and were also downgraded more when on placebo than when on carbazepine.

It was also noted that the group who began on carbazepine improved 58% in their first period on the drug, while those who began on placebo improved only 41% when on carbazepine for the first time, i.e., in their second fortnight. This difference in response is unrelated to the initial degree of the severity of pain which, as has already been pointed out, shows a roughly similar distribution in the two groups (Table I).

If one regards the first period of two weeks as a traditional type of trial (and not 'cross-over') in which two groups with similar characteristics at the outset are given carbazepine or placebo in consecutive order, then the result of the trial is even more clear-cut: the carbazepine group were upgraded 58% of a possible 89 grades and downgraded 0% of a possible 19, while the placebo group were upgraded by 26% of a possible 86 grades, and downgraded 12% of a possible 16. The difference of 32% in upgrading is statistically significant (P<0.01). Because it is free from the ambiguities that may arise in the interpretation of cross-over procedures this is also a valid conclusion to be derived from the data on the severity of pain in this trial.

NUMBER OF PAROXYSMS It was not found possible to keep to exact numerical answers to questions about the number of paroxysms of pain, and the patients' replies were therefore categorised 0, 1, 2 or 3, where 0 = nil and 3 = ‘every half hour’, ‘innumerable’, ‘hundreds’. Using these categories as had been done for severity of pain, upgrading and downgrading were calculated and expressed as percentages of the amount possible. The carbazepine group improved 68% of the possible amount in the first period, and the placebo group only 26%.

TRIGGER MECHANISMS The triggering effect on the pain by eating, talking, contact, and draughts was considered at each attendance, and when this information was collated at the end of the trial it was possible to give the actual disappearance or appearance of triggering factors as percentages of the amount of disappearance or appearance possible. For all four triggering factors combined, the carbazepine group showed 68% upgrading as compared with 40% in the placebo group, and 2% downgrading.
as compared with 20%, both statistically significant figures (P = 0.05).

A valid and simple comparison of the response of tic douloureux to carbazepine as against placebo seems to be in the first two weeks of the trial, comparing 36 patients on carbazepine with 34 on placebo. The results are summarized in Table II.

**TABLE II**

**SUMMARY OF RESULTS**

<table>
<thead>
<tr>
<th>Actual Improvement as Percentage of Possible Amounts</th>
<th>Carbazepine</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severity of pain</td>
<td>58</td>
<td>26 S.</td>
</tr>
<tr>
<td>Number of paroxysms</td>
<td>68</td>
<td>26 S.</td>
</tr>
<tr>
<td>Disappearance of triggers</td>
<td>71</td>
<td>41 S.</td>
</tr>
<tr>
<td>Eating</td>
<td>62</td>
<td>48 N.S.</td>
</tr>
<tr>
<td>Talking</td>
<td>82</td>
<td>38 S.</td>
</tr>
<tr>
<td>Draughts</td>
<td>67</td>
<td>42 N.S.</td>
</tr>
<tr>
<td>Number of triggers becoming inactive</td>
<td>68</td>
<td>40 S.</td>
</tr>
</tbody>
</table>

$S$ = significantly different at the 0.05 level.

N.S. = not significantly different.

SIDE EFFECTS Fifty per cent of patients experienced at least one side effect on carbazepine as against 24% on placebo. In the case of carbazepine, giddiness was the most frequent side effect, occurring in 30% of patients in the first period on the drug and dropping to 23% during the second period. Unsteadiness and drowsiness were the next most frequent side effects, occurring in 15% of patients and not necessarily together.

The most important side effect, which was seen in this trial once only and led to the withdrawal from the trial of this patient, is the occurrence of a rash. In this case it was erythematous, but it can be morbilliform or urticarial. We regarded its appearance as an indication for stopping the drug. Two deaths from agranulocytosis have been reported in patients taking carbazepine and one had had a rash previously (Spillane, 1964; Donaldson and Graham, 1965).

**SUMMARY**

In a controlled trial, carbazepine has been shown to be much more effective than a placebo in the treatment of trigeminal neuralgia.

We wish to thank Dr. M. J. McArdle and Dr. J. D. Spillane for their help and encouragement in carrying out this trial; we are grateful to Dr. Lewis-Faning for his help in the analysis of the statistical data. Our thanks are due to Dr. Alan Galbraith, of the Medical Department, Geigy Pharmaceutical Company Limited, for generous supplies of carbazepine (Tegretol).

**REFERENCES**


Clinical trial of carbazepine (tegretol) in trigeminal neuralgia.

F G Campbell, J G Graham and K J Zilkha

*J Neurol Neurosurg Psychiatry* 1966 29: 265-267
doi: 10.1136/jnnp.29.3.265

Updated information and services can be found at:
http://jnnp.bmj.com/content/29/3/265.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/